Please ensure Javascript is enabled for purposes of website accessibility

Why Charlotte's Web Stock Slipped Again Today

By Keith Speights - Aug 15, 2019 at 4:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be worried that the company's growth could be stymied by the FDA's sluggishness in establishing CBD regulations.

What happened

Shares of Charlotte's Web Holdings (CWBHF -15.67%) slipped 6.2% lower on Thursday after falling as much as 13.7% earlier in the day. This marked the second consecutive day of large declines after the cannabidiol (CBD) leader reported its second-quarter results on Wednesday morning. The continued sell-off appears to be due, in large part, to investors' worries that Charlotte's Web's growth could be limited until the U.S. Food and Drug Administration (FDA) finalizes its regulations for CBD.

So what

Charlotte's Web's products are now carried in more than 8,000 retail locations. However, many of those locations, including CVS Health and Kroger, only sell the company's topical CBD products. These major retailers don't want to risk running afoul of the FDA, which has expressed its displeasure about CBD food-supplement products that make misleading health claims.

Cannabis, bottle, and dropper

Image source: Getty Images.

The problem is that around 80% of Charlotte's Web's sales are generated by its CBD supplement products. Charlotte's Web CEO Deanie Elsner acknowledged in the company's Q2 conference call that big retailers aren't going to market its CBD supplements until the FDA hands down its regulations. Many investors appear to be focusing on the uncertainty about when the FDA decision will be made.

However, Elsner maintained that Charlotte's Web has multiple pathways to grow while it awaits the FDA's CBD regulations. She also expects that whenever those regulations are finalized, it will present a major catalyst for Charlotte's Web.

The company's full-year 2019 revenue guidance appears to back up Elsner's take. Charlotte's Web projects 2019 revenue will be between $120 million and $170 million. That wide range reflects the question marks surrounding what the FDA will do. Even on the low end of that range, though, it reflects nearly 73% year-over-year revenue growth.

Now what

Investors, like Charlotte's Web and its retail partners, will have to wait to see what the FDA decides regarding CBD regulations. In the meantime, it doesn't seem likely that the agency will clamp down on Charlotte's Web for marketing its CBD supplements. The company continues to avoid making any unwarranted health claims that might get it into trouble.

Charlotte's Web should add even more retail locations to its distribution network in the remaining months of 2019. In addition, the company thinks it will grow revenue at a faster pace than operating expenses. The stock's pullback over the last couple of days could present an attractive buying opportunity for patient investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Charlotte's Web Holdings, Inc. Stock Quote
Charlotte's Web Holdings, Inc.
$0.50 (-15.67%) $0.09
The Kroger Co. Stock Quote
The Kroger Co.
$53.39 (-1.53%) $0.83
CVS Health Corporation Stock Quote
CVS Health Corporation
$97.48 (-0.78%) $0.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.